Li et al. reported on the use of PD-1 inhibitors in combination with CD19-directed CAR-T cell therapy for 14 patients with heavily pretreated B-ALL who initially had poor response to CD19 CAR-T therapy [121, 122]. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.